Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
Status:
Withdrawn
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of Azithromycin (a macrolide class
antibiotic), given three times weekly, for patients with active moderate-severe, non
sight-threatening, Graves Orbitopathy.
Indices for follow-up will include:
- Clinical activity score
- Anti-TSH receptor antibody levels
- Thickening of extraocular muscles per ultrasound
- Quality of life score for Graves Orbitopathy patients